Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin’s Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma: the Non-Hodgkin’s Lymphoma Classification Project. Blood1997;89:3909–3918.
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma: the Non-Hodgkin’s Lymphoma Classification Project. Blood1997;89:3909–3918.
)| false
HallekMChesonBDCatovskyD. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood2008;111:5446–5456.
HallekMChesonBDCatovskyD. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood2008;111:5446–5456.
)| false
TsimberidouAMWenSO’BrienS. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas MD Anderson Cancer Center. J Clin Oncol2007;25:4648–4656.
TsimberidouAMWenSO’BrienS. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas MD Anderson Cancer Center. J Clin Oncol2007;25:4648–4656.
)| false
BaliakasPIskasMGardinerA. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. Am J Hematol2014;89:249–255.
BaliakasPIskasMGardinerA. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. Am J Hematol2014;89:249–255.
)| false
WoyachJARuppertASLozanskiG. Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: a single-center experience of 267 patients [abstract]. J Clin Oncol2014;32(15_suppl):Abstract 7010.
WoyachJARuppertASLozanskiG. Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: a single-center experience of 267 patients [abstract]. J Clin Oncol2014;32(15_suppl):Abstract 7010.
)| false
ThompsonPAWierdaWGFerrajoliA. Complex karyotype, rather than del(17p), is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib-based regimens [abstract]. Blood2014;124:Abstract 22.
ThompsonPAWierdaWGFerrajoliA. Complex karyotype, rather than del(17p), is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib-based regimens [abstract]. Blood2014;124:Abstract 22.
)| false
DickerFSchnittgerSHaferlachT. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood2006;108:3152–3160.
DickerFSchnittgerSHaferlachT. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood2006;108:3152–3160.
)| false
PutNKoningsPRackK. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Cancer2009;48:843–853.
PutNKoningsPRackK. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Cancer2009;48:843–853.
)| false
StruskiSGervaisCHeliasC. Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities. Leukemia2009;23:617–619.
StruskiSGervaisCHeliasC. Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities. Leukemia2009;23:617–619.
)| false
HeeremaNAByrdJCDal CinPS. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) study. Cancer Genet Cytogenet2010;203:134–140.
HeeremaNAByrdJCDal CinPS. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) study. Cancer Genet Cytogenet2010;203:134–140.
)| false
CrespoMBoschFVillamorN. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med2003;348:1764–1775.
CrespoMBoschFVillamorN. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med2003;348:1764–1775.
)| false
DamleRNWasilTFaisF. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood1999;94:1840–1847.
DamleRNWasilTFaisF. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood1999;94:1840–1847.
)| false
HallekMLangenmayerINerlC. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood1999;93:1732–1737.
HallekMLangenmayerINerlC. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood1999;93:1732–1737.
)| false
HallekMWandersLOstwaldM. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma1996;22:439–447.
HallekMWandersLOstwaldM. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma1996;22:439–447.
)| false
HamblinTJDavisZGardinerA. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood1999;94:1848–1854.
HamblinTJDavisZGardinerA. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood1999;94:1848–1854.
)| false
HamblinTJOrchardJAIbbotsonRE. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood2002;99:1023–1029.
HamblinTJOrchardJAIbbotsonRE. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood2002;99:1023–1029.
)| false
RassentiLZHuynhLToyTL. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med2004;351:893–901.
RassentiLZHuynhLToyTL. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med2004;351:893–901.
)| false
BulianPShanafeltTDFeganC. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol2014;32:897–904.
BulianPShanafeltTDFeganC. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol2014;32:897–904.
)| false
KroberABloehdornJHafnerS. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol2006;24:969–975.
KroberABloehdornJHafnerS. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol2006;24:969–975.
)| false
OscierDWadeRDavisZ. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica2010;95:1705–1712.
OscierDWadeRDavisZ. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica2010;95:1705–1712.
)| false
OscierDGGardinerACMouldSJ. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood2002;100:1177–1184.
OscierDGGardinerACMouldSJ. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood2002;100:1177–1184.
)| false
GentileMMauroFRCalabreseE. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol2005;130:549–557.
GentileMMauroFRCalabreseE. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol2005;130:549–557.
)| false
Del PrincipeMIDel PoetaGBuccisanoF. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood2006;108:853–861.
Del PrincipeMIDel PoetaGBuccisanoF. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood2006;108:853–861.
)| false
RassentiLZJainSKeatingMJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood2008;112:1923–1930.
RassentiLZJainSKeatingMJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood2008;112:1923–1930.
)| false
CorcoranMParkerAOrchardJ. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica2005;90:1078–1088.
CorcoranMParkerAOrchardJ. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica2005;90:1078–1088.
)| false
ClausRLucasDMStilgenbauerS. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol2012;30:2483–2491.
ClausRLucasDMStilgenbauerS. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol2012;30:2483–2491.
)| false
ClausRLucasDMRuppertAS. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood2014;124:42–48.
ClausRLucasDMRuppertAS. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood2014;124:42–48.
)| false
TamCSO’BrienSWierdaW. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood2008;112:975–980.
TamCSO’BrienSWierdaW. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood2008;112:975–980.
)| false
TsimberidouAMTamCWierdaW. Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl) [abstract]. J Clin Oncol2007;25:Abstract 7034.
TsimberidouAMTamCWierdaW. Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl) [abstract]. J Clin Oncol2007;25:Abstract 7034.
)| false
WierdaWGO’BrienSWangX. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol2009;27:1637–1643.
WierdaWGO’BrienSWangX. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol2009;27:1637–1643.
)| false
WierdaWGO’BrienSWangX. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood2007;109:4679–4685.
WierdaWGO’BrienSWangX. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood2007;109:4679–4685.
)| false
MolicaSMauroFRCalleaV. The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica2010;95:464–469.
MolicaSMauroFRCalleaV. The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica2010;95:464–469.
)| false
NeilsonJRAuerRWhiteD. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia1997;11:1929–1932.
NeilsonJRAuerRWhiteD. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia1997;11:1929–1932.
)| false
AustenBSkowronskaABakerC. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol2007;25:5448–5457.
AustenBSkowronskaABakerC. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol2007;25:5448–5457.
)| false
TsimberidouAMTamCAbruzzoLV. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer2009;115:373–380.
TsimberidouAMTamCAbruzzoLV. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer2009;115:373–380.
)| false
HallekMFischerKFingerle-RowsonG. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet2010;376:1164–1174.
HallekMFischerKFingerle-RowsonG. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet2010;376:1164–1174.
)| false
CatovskyDRichardsSMatutesE. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet2007;370:230–239.
CatovskyDRichardsSMatutesE. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet2007;370:230–239.
)| false
StilgenbauerSSanderSBullingerL. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica2007;92:1242–1245.
StilgenbauerSSanderSBullingerL. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica2007;92:1242–1245.
)| false
WierdaWGO’BrienSWangX. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol2011;29:4088–4095.
WierdaWGO’BrienSWangX. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol2011;29:4088–4095.
)| false
StilgenbauerSSchnaiterAPaschkaP. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood2014;123:3247–3254.
StilgenbauerSSchnaiterAPaschkaP. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood2014;123:3247–3254.
)| false
GonzalezDMartinezPWadeR. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol2011;29:2223–2229.
GonzalezDMartinezPWadeR. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol2011;29:2223–2229.
)| false
RossiDCerriMDeambrogiC. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res2009;15:995–1004.
RossiDCerriMDeambrogiC. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res2009;15:995–1004.
)| false
WoyachJARuppertASHeeremaNA. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol2011;29:1349–1355.
WoyachJARuppertASHeeremaNA. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol2011;29:1349–1355.
)| false
FabbriGRasiSRossiD. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med2011;208:1389–1401.
FabbriGRasiSRossiD. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med2011;208:1389–1401.
)| false
RossiDFangazioMRasiS. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood2012;119:2854–2862.
RossiDFangazioMRasiS. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood2012;119:2854–2862.
)| false
RossiDRasiSSpinaV. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood2013;121:1403–1412.
RossiDRasiSSpinaV. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood2013;121:1403–1412.
)| false
SchnaiterAPaschkaPRossiM. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood2013;122:1266–1270.
SchnaiterAPaschkaPRossiM. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood2013;122:1266–1270.
)| false
RossiDRasiSSpinaV. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol2012;158:426–429.
RossiDRasiSSpinaV. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol2012;158:426–429.
)| false
VillamorNCondeLMartinez-TrillosA. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia2013;27:1100–1106.
VillamorNCondeLMartinez-TrillosA. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia2013;27:1100–1106.
)| false
ConteMJBowenDAWisemanGA. Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma2014;55:2079–2084.
ConteMJBowenDAWisemanGA. Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma2014;55:2079–2084.
)| false
FalchiLKeatingMJMaromEM. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood2014;123:2783–2790.
FalchiLKeatingMJMaromEM. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood2014;123:2783–2790.
)| false
BinetJAuquierADighieroG. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer1981;48:198–206.
BinetJAuquierADighieroG. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer1981;48:198–206.
)| false
ChesonBDBennettJMGreverM. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood1996;87:4990–4997.
ChesonBDBennettJMGreverM. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood1996;87:4990–4997.
)| false
ChesonBDByrdJCRaiKR. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol2012;30:2820–2822.
ChesonBDByrdJCRaiKR. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol2012;30:2820–2822.
)| false
WoyachJASmuckerKSmithLL. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood2014;123:1810–1817.
WoyachJASmuckerKSmithLL. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood2014;123:1810–1817.
)| false
KovacsGBoettcherSBahloJ. Value of minimal residual disease (MRD) negative status at response evaluation in chronic lymphocytic leukemia (CLL): combined analysis of two phase III studies of the German CLL Study Group (GCLLSG) [abstract]. Blood2014;124:Abstract 23.
KovacsGBoettcherSBahloJ. Value of minimal residual disease (MRD) negative status at response evaluation in chronic lymphocytic leukemia (CLL): combined analysis of two phase III studies of the German CLL Study Group (GCLLSG) [abstract]. Blood2014;124:Abstract 23.
)| false
BurgerJAMontserratE. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood2013;121:1501–1509.
BurgerJAMontserratE. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood2013;121:1501–1509.
)| false
FlynnJMByrdJCKippsTJ. Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): results of the phase II GAGE (GAO4768g) trial [abstract]. J Clin Oncol2014;32(Suppl 15):Abstract 7083.
FlynnJMByrdJCKippsTJ. Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): results of the phase II GAGE (GAO4768g) trial [abstract]. J Clin Oncol2014;32(Suppl 15):Abstract 7083.
)| false
RobakTJanssensAGovindbabuK. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911) [abstract]. Blood2013;122:Abstract 528.
RobakTJanssensAGovindbabuK. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911) [abstract]. Blood2013;122:Abstract 528.
)| false
O’BrienSFurmanRRCoutreSE. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol2014;15:48–58.
O’BrienSFurmanRRCoutreSE. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol2014;15:48–58.
)| false
O’BrienSMFurmanRRCoutreSE. Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease [abstract]. J Clin Oncol2014;32(15_suppl):Abstract 7014.
O’BrienSMFurmanRRCoutreSE. Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease [abstract]. J Clin Oncol2014;32(15_suppl):Abstract 7014.
)| false
ZelenetzADLamannaNKippsTJ. A phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract]. Blood2014;124:Abstract 1986.
ZelenetzADLamannaNKippsTJ. A phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract]. Blood2014;124:Abstract 1986.
)| false
O’BrienSLamannaNKippsTJ. Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naïve patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract]. Blood2014;124:Abstract 1994.
O’BrienSLamannaNKippsTJ. Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naïve patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract]. Blood2014;124:Abstract 1994.
)| false
BrownJRByrdJCCoutreSE. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood2014;123:3390–3397.
BrownJRByrdJCCoutreSE. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood2014;123:3390–3397.
)| false
BrownJRHillmenPO’BrienS. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma [abstract]. Blood2014;124:Abstract 3331.
BrownJRHillmenPO’BrienS. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma [abstract]. Blood2014;124:Abstract 3331.
)| false
O’BrienSJonesJACoutreS. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 trial [abstract]. Blood2014;124:Abstract 327.
O’BrienSJonesJACoutreS. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 trial [abstract]. Blood2014;124:Abstract 327.
)| false
SharmanJPCoutreSEFurmanRR. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract]. Blood2014;124:Abstract 330.
SharmanJPCoutreSEFurmanRR. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract]. Blood2014;124:Abstract 330.
)| false
SharmanJPCoutreSEFurmanRR. Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: results from a phase 3, randomized, double-blind, placebo-controlled trial [abstract]. J Clin Oncol2014;32(15_suppl):Abstract 7011.
SharmanJPCoutreSEFurmanRR. Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: results from a phase 3, randomized, double-blind, placebo-controlled trial [abstract]. J Clin Oncol2014;32(15_suppl):Abstract 7011.
)| false
WierdaWGKippsTJMayerJ. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia [abstract]. Blood2010;116:Abstract 921.
WierdaWGKippsTJMayerJ. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia [abstract]. Blood2010;116:Abstract 921.
)| false
WierdaWGPadmanabhanSChanGW. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study. Blood2011;118:5126–5129.
WierdaWGPadmanabhanSChanGW. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study. Blood2011;118:5126–5129.
)| false
CartronGde GuibertSDilhuydyMS. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood2014;124:2196–2202.
CartronGde GuibertSDilhuydyMS. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood2014;124:2196–2202.
)| false
GoedeVEngelkeAFischerK. Salvage therapy with obinutuzumab (GA101) plus chlorambucil (Clb) after treatment failure of Clb alone in patients with chronic lymphocytic leukemia (CLL) and comorbidities: results of the CLL11 study [abstract]. Blood2014;124:Abstract 3327.
GoedeVEngelkeAFischerK. Salvage therapy with obinutuzumab (GA101) plus chlorambucil (Clb) after treatment failure of Clb alone in patients with chronic lymphocytic leukemia (CLL) and comorbidities: results of the CLL11 study [abstract]. Blood2014;124:Abstract 3327.
)| false
KhouriIFKeatingMJSalibaRMChamplinRE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy2002;4:217–221.
KhouriIFKeatingMJSalibaRMChamplinRE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy2002;4:217–221.
)| false
KhouriIFSalibaRMAdmirandJ. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol2007;137:355–363.
KhouriIFSalibaRMAdmirandJ. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol2007;137:355–363.
)| false
MorenoCVillamorNColomerD. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol2005;23:3433–3438.
MorenoCVillamorNColomerD. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol2005;23:3433–3438.
)| false
ScheteligJvan BiezenABrandR. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol2008;26:5094–5100.
ScheteligJvan BiezenABrandR. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol2008;26:5094–5100.
)| false
DregerPDohnerHRitgenM. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood2010;116:2438–2447.
DregerPDohnerHRitgenM. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood2010;116:2438–2447.
)| false
National Cancer Institute. SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia. Bethesda, MD: 2012. Available at: http://seer.cancer.gov/statfacts/html/clyl.html. Accessed August 2012.
National Cancer Institute. SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia. Bethesda, MD: 2012. Available at: http://seer.cancer.gov/statfacts/html/clyl.html. Accessed August 2012.
)| false
EichhorstBFBuschRStilgenbauerS. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood2009;114:3382–3391.
EichhorstBFBuschRStilgenbauerS. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood2009;114:3382–3391.
)| false
GoedeVCramerPBuschR. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica2014;99:1095–1100.
GoedeVCramerPBuschR. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica2014;99:1095–1100.
)| false
Satram-HoangSReyesCHoangKQ. Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database. Ann Hematol2014;93:1335–1344.
Satram-HoangSReyesCHoangKQ. Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database. Ann Hematol2014;93:1335–1344.
)| false
SalviFMillerMDGrilliA. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc2008;56:1926–1931.
SalviFMillerMDGrilliA. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc2008;56:1926–1931.
)| false
HillmenPGribbenJGFollowsGA. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol2014;32:1236–1241.
HillmenPGribbenJGFollowsGA. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol2014;32:1236–1241.
)| false
FoaRGiudiceIDCuneoA. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol2014;89:480–486.
FoaRGiudiceIDCuneoA. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol2014;89:480–486.
)| false
FischerKCramerPBuschR. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol2012;30:3209–3216.
FischerKCramerPBuschR. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol2012;30:3209–3216.
)| false
EichhorstBFinkAMBuschR. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study) [abstract]. Blood2014;124:Abstract 19.
EichhorstBFinkAMBuschR. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study) [abstract]. Blood2014;124:Abstract 19.
)| false
TsimberidouAMO’BrienSKantarjianHM. Hodgkin transformation of chronic lymphocytic leukemia: the M D Anderson Cancer Center experience. Cancer2006;107:1294–1302.
TsimberidouAMO’BrienSKantarjianHM. Hodgkin transformation of chronic lymphocytic leukemia: the M D Anderson Cancer Center experience. Cancer2006;107:1294–1302.
)| false
ChigrinovaERinaldiAKweeI. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood2013;122:2673–2682.
ChigrinovaERinaldiAKweeI. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood2013;122:2673–2682.
)| false
TsimberidouAMO’BrienSKhouriI. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol2006;24:2343–2351.
TsimberidouAMO’BrienSKhouriI. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol2006;24:2343–2351.
)| false
TadmorTShvidelLGoldschmidtN. Hodgkin’s variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group. Anticancer Res2014;34:785–790.
TadmorTShvidelLGoldschmidtN. Hodgkin’s variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group. Anticancer Res2014;34:785–790.
)| false
TsimberidouAMKantarjianHMCortesJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer2003;97:1711–1720.
TsimberidouAMKantarjianHMCortesJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer2003;97:1711–1720.
)| false
TsimberidouAMWierdaWGPlunkettW. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol2008;26:196–203.
TsimberidouAMWierdaWGPlunkettW. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol2008;26:196–203.
)| false
CwynarskiKvan BiezenAde WreedeL. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter’s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol2012;30:2211–2217.
CwynarskiKvan BiezenAde WreedeL. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter’s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol2012;30:2211–2217.
)| false
